Last edition
News about
South Africa pushes for local manufacturing of Gilead's HIV prevention drug
Gilead Sciences’ long-acting HIV prevention drug, lenacapavir, could soon be produced in South Africa as the government pushes to expand regional manufacturing and improve access to the therapy.
Ipsen receives positive EMA panel opinion for Ojemda to treat paediatric low-grade glioma
European Medicines Agency’s CHMP recommends conditional approval of Ojemda (tovorafenib) for children with BRAF-altered paediatric low-grade glioma, offering a potential targeted therapy option for relapsed or refractory cases.
Novocure secures Japan insurance reimbursement for Optune Lua in advanced lung cancer treatment
Novocure receives reimbursement approval from Japan’s Ministry of Health, Labour and Welfare of Japan for Optune Lua, enabling insured access for advanced NSCLC patients using Tumour Treating Fields therapy.
The FDA lifted the clinical hold on Intellia’s phase III MAGNITUDE trial evaluating CRISPR-based therapy nex-z for transthyretin amyloidosis with cardiomyopathy, enabling the company to resume patient enrollment with enhanced safety measures.
Akeso and Inovio Pharmaceuticals Partner to Develop Combination Therapy for Glioblastoma
Akeso and Inovio Pharmaceuticals have entered into a clinical collaboration to evaluate cadonilimab with INO-5412 in glioblastoma. The combination will be studied in the phase-II INSIGhT trial sponsored by Dana-Farber Cancer Institute, building on prior positive data.
Glenmark Specialty SA Receives US FDA Approval for Fluticasone Propionate Inhalation Aerosol USP
Glenmark Pharmaceuticals’s subsidiary Glenmark Specialty SA has received approval from the US Food and Drug Administration (FDA) for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, along with 180-day Competitive Generic Therapy exclusivity. The product has been deemed bioequivalent and therapeutically equivalent to Flovent HFA.
GSK completes acquisition of RAPT Therapeutics
GSK has completed the acquisition of RAPT Therapeutics, adding ozureprubart, a long-acting anti-IgE monoclonal antibody, to its pipeline. The candidate is currently in phase-II(b) development for prophylactic protection against food allergens, strengthening GSK’s immunology portfolio.
Moderna Inc. Secures Positive CHMP Opinion for First Flu Covid Combination Vaccine
Moderna Inc. has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending marketing authorisation for mCOMBRIAX (mRNA-1083) in the European Union.
Pharmacy Council of India Announces 2026 Theme for National Pharmacy Education Day
The Pharmacy Council of India (PCI) has unveiled the official theme for Pharma Anveshan 2026, an event to be organised nationwide by pharmacy institutions as part of National Pharmacy Education Day celebrations on March 6, 2026.
Ono Pharmaceutical Partners with Congruence Therapeutics for Neurology and Immunology Drug Discovery
Ono Pharmaceutical has expanded its collaboration with Congruence Therapeutics, leveraging the Revenir platform to discover small molecule modulators in neurology and immunology. Ono will hold exclusive worldwide option rights for development and commercialisation of resulting candidates.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy